Sofinnova Partners has announced the final close of Sofinnova Crossover II at €725m ($815m), exceeding its original target.
The fund will back late-stage companies through clinical development, global expansion and commercialisation.
It will focus mainly on European clinical-stage biopharma and medtech firms, with selective investments in the US and other markets.
Sofinnova expects to invest in around 15 companies and has already backed Hemab Therapeutics, CellCentric and Neurent Medical.
Antoine Papiernik, Chair and Managing Partner of Sofinnova Partners, said the fund’s scale “reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets.”